(RTTNews) - Monday, Sanofi (SNY) commenced construction of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, leveraging advanced digital technologies and artificial intelligence across manufacturing and quality processes.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.